The FibrilRuler™ assay
The FibrilRuler™ assay
In neurodegenerative diseases such as Alzheimer’s and Parkinson’s, pathological protein aggregates form years before clinical symptoms become apparent.
We have developed FibrilPaint, a highly specific peptide that selectively binds amyloid fibrils.
Our patented biomarker assay, FibrilRuler™, uses FibrilPaint to detect these aggregates in cerebrospinal fluid (CSF) and blood, enabling early detection and precise measurement of disease progression.
Interested in working together? Get in touch
Supported by